Background. Methylation of the human papillomavirus (HPV) DNA has been proposed as a novel biomarker. Here, we correlated the mean methylation level of 12 CpG sites within the L1 gene, to the histological grade of cervical precancer and cancer. We assessed whether HPV L1 gene methylation can predict the presence of high-grade disease at histology in women testing positive for HPV16 genotype.
The introduction of systematic call and recall screening programs has resulted in a profound decrease in the incidence and mortality from invasive cervical cancer as preinvasive lesions (cervical intraepithelial neoplasia [CIN] ) can be treated appropriately [1, 2] . Despite the high efficacy of screening in preventing cervical cancer, this has traditionally relied on cytology that is known to have limitations.
Establishing that persistent infection with high-risk human papillomavirus (HPV) is causally associated with cervical cancer has led to major advances in primary and secondary prevention. It is now recognized that the use of the HPV DNA test in primary screening is likely to offer 60%-70% greater protection against invasive cancer compared with cytology-based screening [3] , while the best policy in further triaging women with positive results at HPV-based screening is unclear.
New biomarkers, exploring the viral genome and life cycle together with its interactions with the host, have the potential to permit a more comprehensive understanding of the disease process. These tests may enable a more accurate detection of clinically significant preinvasive lesions and a more personalized identification and management of lesions with true progressive carcinogenic potential [4] [5] [6] . Some target genes in the HPV genome play pivotal roles in the viral life cycle and ongogenesis [7, 8] . Methylation of the viral DNA has been recently proposed as a novel biomarker with encouraging results. The quantification of the percentage of cytosines with a covalently added methyl-group at individual CpG (Cytosine-phosphate-Guanine) dinucleotides reflects the degree of epigenetic changes of the viral genome.
Research in the quantification of methylation at different CpG sites and genes produced contradictory results, while the methylation threshold varied across studies [9] [10] [11] . Although 2 small studies suggested that increased methylation was associated with high-grade squamous intraepithelial lesions (HSILs) [9, 11] , others examining CpG sites within the upstream regulatory region (URR) documented that it is the lack of methylation that associates with disease progression [12, 13] . Two further studies on the Guanacaste Costa Rica cohort reported that high methylation at the L1, L2, and E2-4 CpG sites increased the risk of CIN3 by 50 times compared with low methylation (odds ratio [OR], 52; 95% confidence interval [CI], 4.0-670). Increased methylation levels predicted both the presence of HSIL in women with positive HPV16 infections as well as the risk for development of future CIN2+ [10, 14] .
This prospective study aims to assess whether pyrosequencing of the HPV16 L1 gene and quantification of the methylation level of specific CpGs could predict the presence of high-grade disease at histology in women testing positive for the HPV16 genotype. More specifically, we aim to correlate the mean methylation level to the histological grade and to determine its accuracy in predicting the disease severity by establishing optimum methylation cutoffs.
METHODS

Study Population
We conducted a multicentric prospective study that recruited in 3 University Hospitals (Ioannina/Athens, Greece and Imperial College London, United Kingdom). Ethical approval was obtained and all patients gave consent (Bioethics Committee, Greece and National Research Ethics Service Committee London-Fulham; 13/LO/0126).
We included nonpregnant women, 21-67 years of age who attended the gynecology clinics (May 2013 to 2015). All cervical samples that tested positive for HPV16 DNA typing and had available histology (punch biopsy or conisation-gold standard) were included. If histology was available from both biopsies and cones, the most severe lesion was used. The histological diagnoses included the following groups: normal, CIN1, CIN2, CIN3, squamous cell carcinoma (SCC), and adenocarcinoma.
Women were included irrespective of their ethnicity and smoking habits. Women who were human immunodeficiency virus (HIV) or hepatitis B/C positive, with autoimmune disorders, or had a previous history of conisation were excluded.
Sample Collection and Methods
We prospectively collected patient characteristics and recorded the cytological, colposcopic, and histological findings. We obtained a liquid-based cytology sample (LBC, ThinPrep Pap Test, Hologic) that was prepared on a TP2000 Processor and was reported by trained cytopathologists according to the Bethesda 2001 system (TBS2001) [15] . The residual LBC sample was aliquoted and stored at 4°C until further use.
The HPV DNA typing was performed with CLART HPV2 kit (Genomica, Spain) which is validated to genotype 20 high-risk HPV types (16, 18, 26, 31, 33, 35, 39, 45, 51, 52, 53, 56, 58, 59, 66, 68, 70, 73, 82 , and 85) and 15 low-risk HPV types (6, 11, 40, 42, 43, 44, 54, 61, 62, 71, 72, 81, 83, 84 , and 89). The extracted DNA concentrations were measured with Quant-iT PicoGreen dsDNA Assay Kit (Thermo Fisher Scientific).
DNAs were then bisulphite converted using the EpiTect Bisulfite Kit (Qiagen), according to the manufacturer's instructions and stored at -80°C. Biotin-labeled primer sets and polymerase chain reaction conditions [14] were used as previously described to amplify HPV16 L1 region. DNA from the cervical cancer cell line SiHa that contains integrated HPV16 genome [16] was extracted and bisulfite converted. The methylation quantification was performed by Pyrosequencing technology (PyroMark Q24, Qiagen), which provides a site-specific quantification of methylation at individual CpG sites. The analysis performed in the present study included 12 CpGs mapped in the HPV16 L1 ORF and specifically 5611, 5726, 5927, 6367, 6389, 6457, 6581, 6650, 6796, 7091, 7136, 7145 of clinical samples' and SiHa DNA. The pyrograms were analyzed using the CpG mode of the PyroMark Q24 software, to determine the percentage methylation at each site as well as the overall mean methylation.
Statistical Analysis
For each included sample, we calculated the mean methylation level (ie, the mean value of the measured methylation percentages) by dividing the sum of the percentage methylation levels for all positions (P01M-P12M) by the number of positions (ie, 12). We produced box and whisker plots of the mean methylation and the standard deviation (SD) and range for each histological group. Each histological category was given a number starting from 1 (negative) and ending to 6 (SCC). We performed a regression analysis [17] to identify and describe the linear mathematical equation governing the correlation between mean methylation percentage and histological grade that includes the intercept and slope of the line. We used t test to determine significance. This mathematical formula was developed with the aim to predict the histological grade from the mean methylation measured. We further produced a fit plot of the mean methylation and the histological grades to describe the linear model, the confidence limits of the line, and the limits of the prediction accuracy. We used unadjusted and adjusted R 2 to describe the performance of the regression analysis and the fit of the line to the data with a value near to 100% describing the perfect fit. We calculated the modified adjusted R 2 that adjusts for several predictors of the model and has been shown to be a better performance metric [17] . These analyses were performed for each of the 12 CpG sites. We further performed a linear regression analysis to explore whether the mean methylation level is affected by age.
We further assessed the discriminative capability for each of the 12 methylation positions (P01M-P12M) in predicting the disease at 4 different histological cutoffs (CIN1+, CIN2+, CIN3+, cancer). We produced receiver operating characteristic (ROC) curves [18] and calculated the area under the curve (AUC), the standard error (SE), and the 95% confidence intervals (CIs). The largest AUC (near to 100%) indicated methylation positions that had the highest prediction of the histological outcome for the chosen cutoff.
We calculated different accuracy parameters for the ability of the mean methylation to detect the presence of disease for 4 histological cutoffs: CIN1+, CIN2+, CIN3+, or cancer. These included the sensitivity, specificity, positive predictive value (PPV), negative predictive value (NPV), the false positive and false negative rates, the overall accuracy (OA), and the positive and negative likelihood ratios. We applied various threshold values starting from 0% and increasing up to 100% using an increment step of 0.1%, as described in our previous studies [19] [20] [21] . We further described the accuracy parameters for different methylation thresholds at each histological cutoffs, and calculated the mean methylation thresholds that optimize the overall accuracy and/or the balance between sensitivity and specificity. We calculated the odds ratio (OR) to describe the likelihood of the histological diagnosis if the mean methylation was above or below a chosen threshold. We subsequently tested the produced algorithm in a small validation set to confirm reproducibility of the results.
We used SAS software version 9.4 for the statistical analysis (SAS Institute) [23, 24] , and the algorithms for the determination of the optimum threshold values were developed in-house within the MATLAB software environment and programming language (MathWorks).
RESULTS
We identified a total of 151 women who tested positive for HPV16 and had histology; 1 was excluded as the histology revealed vaginal intra-epithlial neoplasia grade 2 (VAIN2) ( Table 1 ). The mean age differed among histological groups; women with invasive disease tended to be older (P < .0001). All women with normal cytology had normal findings at histology. None of the women presented with atypical squamous cells of undetermined significance (ASCUS) cytology had HSIL in histology, although 1 Figure 1A ). The HPV16 L1 mean methylation levels (SD) of CIN3+ cases (17.9% ± 7.2%) were significantly higher compared to CIN2 (11.6% ± 6.5%) or CIN1 (9.0% ± 3.5%) histological groups (t test for CIN3+ vs CIN2: t = -4.6, P < .001; CIN3+ vs CIN1: t = -8.9, P < .001). The regression analysis produced a formula to predict the correlation between the mean methylation and the histological grade (mean Table 1 Figure 1B ). The fitted line showed no tolerance as the intercept (-7.65) and slope (7.24) was statistically significant (t test: P < .05 for both). The positive slope of this line (7.65) confirmed that the mean methylation increases with increasing disease grade. Similar trends were found for the disease severity and the mean methylation in each of the individual CpG sites (results not shown). We found that for the 3 subgroups of women with CIN1, CIN2, and CIN3, there was no evidence that the mean methylation level was affected by the age (adjusted R 2 : -0.047, 0.036, and -0.016, respectively). There was a trend toward lower methylation levels in older women with CIN2, but the results were not statistically significant. We quantified the methylation of CpG sites 5611, 5726, 5927, 6367, 6389, 6457, 6581, 6650, 6796, 7091, 7136, and 7145 in the HPV16 L1 gene. We constructed ROC curves to assess the diagnostic utility of the methylation levels of each individual CpG site (assigned P01M-P12M, respectively) and of the mean methylation in predicting the histological diagnosis for the different cutoffs described (CIN1+, CIN2+, CIN3+, cancer) (Figure 2A and 2B ; Supplementary Figures 1-5 ; Supplementary Table 1) . We found the ability to predict the histological diagnosis increased with increased cutoff used and this was consistent for different methylation positions. The AUCs for CIN2+ lesions ranged from 0.66 to 0.82. The lowest AUC value (AUC, 0.66; 95% CI, .57-.76) was observed in site 6367 and the highest (AUC, 0.82; 95% CI, .75-.90) in site 5611 for CIN2+ lesions, while the mean methylation for CIN2+ was 0.81 (95% CI, .74-.88) (Figure 2A; Supplementary Figure 3) . For CIN3+ lesions, the AUCs ranged from 0.71 to 0.86 with the highest value assigned to site 7145 (AUC, 0.86; 95% CI, .80-.92), the lowest to site 5726 (AUC, 0.71; 95% CI, .73-.87), and that for the mean methylation at 0.85 (95% CI, .79-.91) ( Figure 2B; Supplementary Figure 4) . The highest performance was for the histological cutoff of cancer as expected (mean methylation AUC, 0.99; 95% CI, .98-1.00), with limited though clinical use (Supplementary Figures 1, 5) .
We further determined accuracy parameters for different histological cutoffs and described the mean methylation thresholds that optimized overall accuracy and/or the balance between sensitivity and specificity (Table 2; Figure 3 ; Supplementary Figure 6 ). We found that for a histological cutoff of CIN2+ ( Figure 3A) , a mean methylation of 5.6% maximized the OA (82.7%) and achieved optimal sensitivity (97.4%) at the loss of specificity (34.3%). We therefore applied a different mean methylation threshold (10.8%) that optimized the balance between sensitivity (67.8%) and specificity (74.3%) with an overall accuracy of 69.3%. For the prediction of CIN3+, a methylation level of 15.9% optimized the overall accuracy (79.3%), although the sensitivity dropped to 67.1% with specificity being high at 90.0% ( Figure 3B ). The optimal balance of sensitivity and specificity (75.7% and 77.5%, respectively) and PPV and NPV (74.7% and 78.5%, respectively) was achieved for a methylation of 14.0% and OA of 76.7%. Higher methylation levels were used for the detection of cancer cases, where a threshold of 37.9% achieved an OA of 98.6% with a sensitivity of 88.9% and a specificity of 99.3%. The use of a mean methylation threshold of 27.0% optimized sensitivity (100%) at a small loss in specificity (94.3%) and OA (94.7%). With the exception of the histological cutoff of invasive cancer, the odds ratio was higher (OR, 18.39; 95% CI, 7.59-44.54) for a mean methylation threshold of 15.9% for the prediction of CIN3+ (ie, odds for CIN3+ are 18.4 times higher if the mean methylation is above as opposed to less than 15.9%).
We evaluated the algorithm for a validation set of 22 (normal, 5; CIN1, 3; CIN2, 4; CIN3, 8; and SCC, 2) (data not shown). The results were consistent with the training set, although the number of patients was small. For all thresholds, the sensitivity was excellent, although the specificity varied. For the cutoff of CIN2+, the sensitivity was 100% and the specificity was 75.0%, compared to 67.8% and 74.3% in the training set (best balance at 10.8%). All 14 CIN2+ cases were correctly assigned, while 2 of 8 normal/CIN1 cases were misclassified as CIN2+. For the CIN3+ cutoff (maximum accuracy threshold at 15.9%), the sensitivity was 100% and the specificity 66.67% (training sets 67.1% and 90.0%, respectively). The mean methylation enabled the correct classification of the 10 CIN3+ cases, but misclassified as high-grade 4 of 12 CIN2-cases. Results are presented for 2 mean methylation thresholds: one that maximizes the overall accuracy (maxOA) and one that achieves optimal balance between sensitivity and specificity (BaSeSpe). At the level of CIN1+, we present only the optimal equilibrium between specificity and sensitivity, due to the limited number of normal cases included in this study. With the exception of the cancer cutoff, the ability to detect CIN3+ was highest for a mean methylation threshold of 15.9 (odds ratio, 18.4; 95% confidence interval, 7.59-44.54), ie, the odds of CIN3+ are 18.4 higher if the mean methylation is >18.4 as opposed to <18.4).
Abbreviations: BaSeSpe, balance between sensitivity and specificity; CIN, cervical intraepithelial neoplasia; FNR, false negative rate; FPR, false positive rate; maxOA, threshold that maximizes overall accuracy; NA, not applicable; NLR, negative likelihood ratio; NPV, negative predictive value; OA, overall accuracy; PLR, positive likelihood ratio; PPV, positive predictive value.
The knowledge that oncogenic HPV types are causally associated with invasive cervical cancer has initiated research into the viral genome's alterations during the viral life cycle and their interactions with the host genome [25] [26] [27] . The identification of women screened who have CIN2+ has been one of the major challenges of concerted efforts over the last decade, particularly as we are moving toward the use of HPV test at primary screening. The second major challenge was to identify biomarkers and molecular determinants that could distinguish the rare HPV infections that have a true oncogenic malignant potential from those common infections from the same types that resolve spontaneously without leading to disease. Our study suggests that quantification of the methylation levels of 12 CpG sites in the L1 gene with pyrosequencing has the potential to serve as a molecular marker in the prediction of the severity of cervical disease. We studied 150 HPV16-positive cases with histologically confirmed diagnosis. We found that mean methylation level increased with increasing disease severity, while the methylation patterns of each CpG studied did not differ substantially, as previously reported [14] . The mean methylation levels for CIN3+ cases were significantly higher than CIN1 or CIN2 cases, in agreement with previously reported results [14, 28] . Furthermore, we calculated accuracy parameters for various methylation thresholds and defined those that would optimize the diagnostic accuracy of the test.
Various methods of evaluation of viral DNA methylation have been published [9-11, 14, 28-31] . Some researchers used restriction endonucleases in non-bisulfite-based studies [13, 32, 33] , while others employed bisulfite-based assays where cytosine residues from single-stranded DNA are deaminated by sodium bisulfate and converted to uracils with the exception of 5-methyl cytosines that are protected from conversion [34] [35] [36] . In the present study we used bisulfite-treated DNA, and the methylation patterns were analyzed by pyrosequencing, which is a method with reproducible and accurate measures of the degree of methylation at several CpGs in the same amplicon [37] .
There have been considerable efforts to study epigenetic factors affecting viral genes and their associations to cervical cancer and precancer. Researchers have studied CpG sites along HPV genes L1, L2, E2-E4, E5, and URR [9-11, 14, 29, 30, 38] . The results of methylation status vary between studies. Crosssectional studies in diagnostic samples have correlated elevated methylation levels of various genes such as L1, L2, and E2-E4 to the disease severity, while those from enhancer and promoter region of the URR region are less reliable, inconsistent, and heterogenous, often indicating higher methylation frequencies in normal as opposed to HSIL or invasive samples [28] .
Mirabello et al [14] demonstrated that methylation of several CpG sites within L1, L2, and E2-E4 predicted the presence of CIN2 or worse in women with HPV16 infection as well as the risk for future HSIL disease in women testing positive for HPV16. The association between increased DNA methylation in the L1 regions and CIN3+ was also confirmed by Sun et al [30] . Another study that explored 13 CpG sites within the L1 gene reported that higher methylation levels at certain L1 sites were associated with HPV persistence and cervical precancerous progression [38] . Bryant et al [39] , however, stated that although HPV DNA methylation may be a promising biomarker in the triage of HPV-positive cytology samples, its value was less pronounced in young women. Our results did not confirm a correlation between HPV methylation and age, although the analysis was limited due to the small sample size in each group.
We quantified the methylation of 12 CpGs within the L1 gene, and the highest accuracy was found for site 5611, for the prediction of CIN2+, and for site 7145 for the prediction of CIN3+, which is consistent with other reports. Louvanto et al [40] reported high accuracy for sites CpG 6367 and 6389 of the L1 HPV16 region in the prediction of CIN2+ (AUC > .7). Mirabello et al [14] reported an AUC of .82 for CpG 6457, while for Niyazi et al [38] the position 6650 appeared to be the most robust CpG site (AUC > .82). In our study, the estimation of the mean methylation from 12CpG sites did not achieve better accuracy in the prediction of the disease status when compared to loci 5611 and 7145, suggesting that the selective use of few sites that optimize the accuracy consistently across different studies may be the most cost-effective option for the future. The reasons why different L1 sites performed better for CIN2+ and CIN3+ are unclear, although this may be due to the modest sample size. This is a large cohort of patients assessing the methylation levels in the L1 gene in women with histologically confirmed diagnosis of the disease status that also provides data on the methylation thresholds that maximize accuracy of the molecular marker. All samples were analyzed in a single laboratory to minimize bias. The findings add valuable information toward the better understanding of the biological behavior of HPV16 and the "cross-talk" between the viral and host genome leading to increased methylated-CpG content in the L1 gene and disease progression. Although this was a sizeable cohort of patients, there were only a limited number of samples for healthy controls and for some of the histological groups, making interpretation of the results for these groups difficult. Correlation of methylation levels to age was limited due to the limited number of samples in the different histological subgroups. We tested the algorithm in a small validation cohort. Although the results have shown similar trends as the training set, the number of patients was small and we were not able to assess whether there were statistically significant differences. Future studies should assess the reproducibility of these results in large validation sets. Future studies should also analyze serial samples from larger cohorts to further assess the value of methylation as a predictive and diagnostic molecular determinant. The accuracy of HPV methylation should be also compared to that of other currently used tests and biomarkers such as cytology and HPV messenger RNA.
CONCLUSIONS
Elevated methylation levels within the L1 region of the viral DNA are associated with increased disease severity. This molecular determinant may have a role in the triage of screen-detected HPV-positive women that warrant colposcopic investigation, but has the potential to further distinguish the infections and preinvasive lesions most likely to progress, allowing more advanced prognostic risk stratification. This will allow the identification of women who would benefit from colposcopic assessment with or without treatment with a reduction in the unnecessary visits and the reproductive morbidity associated with interventions and treatment [41] [42] [43] [44] [45] . Further serial samples from well-established biobanks should assess the impact of the viral methylation level to the infection/disease progression at various stages of the natural history of the disease. Studies should assess its diagnostic accuracy for different clinical groups and applications.
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